Luke Mcclean’s Post

📢 Friday's Innov8Search Insights quick read for you to get you up to speed quickly on the last week of updates in Life Sciences.📢 There are also continued restructures and redundancies, so please get in touch if you need help. 💥 GE HealthCare is set to acquire Nihon Medi-Physics Co., Ltd. solidifying its presence in Japan’s $7 billion imaging market. NMP specializes in radiopharmaceuticals for neurology, cardiology, and oncology imaging. This move aligns with GE’s precision care strategy, with radiopharmaceuticals highlighted as a key growth driver alongside AI and new products in advancing precision medicine globally. 💥Haemonetics has agreed to sell its whole-blood business to Italy’s GVS for up to $67.1 million. The move is part of Haemonetics’ ongoing portfolio revamp aimed at boosting margins and focusing on high-growth hospital markets. The sale includes manufacturing facilities in California and Mexico, which GVS will continue operating. Analysts view the divestiture as a positive step to enhance Haemonetics’ organic growth and profitability. 💥Eli Lilly and Company's SURMOUNT-5 trial comparing thier Zepbound with Novo Nordisk's Wegovy may influence competition in the obesity treatment market in the future. 💥Edwards Lifesciences projects 8–10% sales growth in 2025, its first full year as a purely structural heart company following the $4.2 billion sale of its Critical Care business. Growth will be driven by advancements in TAVR (transcatheter aortic valve replacement) and TMTT (transcatheter mitral and tricuspid therapies), with TMTT sales expected to grow by 50–60%. Edwards highlighted opportunities in early TAVR interventions and its expanding portfolio of structural heart failure therapies as long-term growth catalysts. 💥Atlas Venture has raised $450 million for its 14th fund, maintaining its focus on early-stage biotech investments. Partner Bruce Booth emphasized the firm’s commitment to disciplined capital allocation and “seed-led venture creation,” avoiding the pitfalls of scaling too quickly. Over the past two years, Atlas has launched 16 biotech companies, supported nearly 50 clinical trials, and seen several key exits and approvals, underscoring the success of its targeted approach amidst a recovering biotech investment landscape. Justin Heath Gemma Ritchard Gemma Lennie-Sharma Innov8Search #medtechnews #biotechnews #pharmanews #innov8search #insights

  Cresco is proud to announce that it has acted as lead counsel for the investment by Novalis Biotech, an early stage venture capital investor in life sciences, in the start-up RheumaFinder, founded by Nicolaas Fosselle (Chief Executive Officer), Dr. Thomas Van Den Berghe (Chief Medical Officer) and Professor Dr. Lennart Jans (Chief Science Officer).   RheumaFinder is a promising start-up developing an AI-powered application that detects signs of rheumatic diseases on a range of radiological imaging modalities. The application analyzes standard medical images requested for any clinical event to detect early signs of structural damage in joints. This early detection tool serves as an invaluable aid to radiologists and rheumatologists, contributing to sustainable healthcare practices by addressing the unmet clinical need of late- and underdiagnosis for rheumatic diseases.   The deal team consisted of Glenn L'hoëst and Dominik Verbist.   More information on this transaction and Rheumafinder’s technology and activities can be found in this article 👉 https://lnkd.in/eGDMA9RH on the website of Rheumafinder (https://lnkd.in/eubwQ7De)   For any further information or questions, please contact Glenn L'hoëst. #cresco #venturecapital #startup #healthcare  

HistoSonics, Inc. is honored to announce the completion of an oversubscribed $102 million Series D financing which will be used to accelerate category defining advancements to our non-invasive histotripsy platforms, support commercial growth in the US and in planned global markets, and initiate the company’s innovative, prospective BOOMBOX Master Study. The round was led by Alpha Wave Global, a world leader in growth stage investments, with participation from new investors Amzak Capital Management and HealthQuest Capital, and existing investors Johnson & Johnson Innovation JJDC Inc, Venture Investors Health Fund, Lumira Ventures, Hatteras Venture Partners, Yonjin Venture, the State of Wisconsin Investment Board, and others. We are excited to have such experienced investors join our team at HistoSonics, and whose investment reinforces our mission to impact patients’ lives with our current liver application and expanded use in kidney, pancreas, prostate, brain and other tumor types. #TeamHisto #Histotripsy #MinimallyInvasiveneIsntMinimalEnough https://lnkd.in/gZy6W9qK

🫀💵More continued positive #funding activity in global #medtech start-up arena as Magenta Medical Ltd. announces $105M USD toward their miniaturized left ventricular assist device (LVAD) system. The Israel based interventional #cardiology start-up has developed the world's smallest catheter mounted self-expanding and retrievable #heartpump targeting high risk percutaneous #coronary interventional patients with #cardiogenic shock. This latest round of funding was led by Novo Nordisk’s investment arm, Novo Holdings, adding to the recent previous $55M infusion last May. Additional investors include with Viking Global Investors and RA Capital Management alongside existing investors OrbiMed, New Enterprise Associates (NEA), JVC Investment Partners, and the ALIVE Israel HealthTech Fund. With very promising safety and efficacy findings displayed at last October’s TCT conference, Magenta will use this latest financing round toward US clinical studies and onward toward future FDA approval. “The Novo Holdings Venture Investment team has been investing in the med tech space since 2003. Magenta meets all of our criteria. The company recently completed a U.S. Early Feasibility Study in high risk-PCI demonstrating their expandable pump, Elevate, can safely be placed and can support cardiac output of an adult.” “The current financing will support further clinical studies and allow Magenta to secure the first US FDA approval. Recent reports indicate that more than 2 million patients could benefit from improved mechanical circulatory support devices so we are excited to see Magenta advance.” -Eric Snyder, Novo Holdings US Venture Investments Partner #structuralheart #interventionalcardiology #medicalinnovation #medtechmoney The Mullings Group Medical Device Network

Congrats to Calgary's Fluid Biomed Inc. on your oversubscribed $27M USD Series A financing round! Another breakthrough innovation from Alberta, Fluid Biomed is revolutionizing brain aneurysm treatment with ReSolv™, a bioabsorbable polymer-based neurovascular stent. Unlike traditional metal stents, this innovative technology dissolves over time, enabling better healing and preserving future treatment options. Developed by leading academic neurosurgeons from the University of Calgary, Dr. John Wong and Dr. Alim Mitha, ReSolv™ has already demonstrated promising results in first-in-human clinical trials. The team will use the funding to further validate the ReSolv™ stent and its proprietary delivery system in expanded patient studies, bringing this life-saving technology closer to the millions of patients affected by brain aneurysms. We’re proud to support homegrown medtech innovation alongside leading life science investors. Looking forward to the next phase of clinical advancement! See the news: https://lnkd.in/gzH4UXNR #InvestmentNews #ABtech #YYCtech #MedTech #BioTech #HealthTech #Innovation #MedicalDevice #LifeSciences #startups #VentureCapital #VC

🧬 Biotech Startup Secures $101M for Revolutionary ALS Treatment TL;DR: • Trace Neuroscience raises $101M led by Third Rock Ventures • Developing RNA-binding therapy targeting UNC13A protein • Clinical trials planned for early 2026 • Led by Eric Green (former Maze Therapeutics, MyoKardia) Exciting developments in the ALS treatment landscape! Trace Neuroscience emerges with groundbreaking antisense therapy targeting the crucial UNC13A protein pathway. Building on recent successes like Biogen's Qalsody, this approach could revolutionize how we treat ALS. The science is compelling: By addressing TDP-43 dysfunction and UNC13A processing, Trace aims to preserve motor neuron function in ALS patients. This could potentially extend beyond ALS to other neurodegenerative conditions. Key investors include: • Third Rock Ventures • Atlas Venture • RA Capital Management • GV (Alphabet's VC arm) This substantial funding signals strong confidence in both the science and leadership team, including renowned researchers Aaron Gitler, Pietro Fratta, and Michael Ward. 💭 What are your thoughts on antisense therapies in neurodegenerative diseases? Have you seen promising developments in your area of expertise? #Biotech #ALS #GeneticMedicine #Innovation #ClinicalTrials #intelligencesimplified #pharma #biotech #biodatastudio

📢 Calling all California-based life sciences startups! California Life Sciences (CLS) is thrilled to announce that we are now accepting pitch applications for our exclusive Investor Partnering Forum, taking place just before the highly anticipated Innovation Showcase. This is a unique opportunity for emerging startups to connect with a curated group of investors, each investor selects up to six companies for one-on-one, 20-minute in-person meetings. Confirmed Investors: AbbVie Ventures, Astellas Pharma Venture Management, Boehringer Ingelheim Venture Fund, Chiesi Global Rare Diseases, Civilization Ventures, Remiges Ventures, Inc., Servier Pharmaceuticals, and Xontogeny. At CLS, we are dedicated to advancing the innovation ecosystem in California, fostering growth, and empowering startups in the life sciences sector. If you're ready to accelerate your journey and connect with key investors, apply today! 🔗Learn more & apply: https://bit.ly/4e2sQcR #Innovation #CaliforniaLifeSciences #partneringforum #pitchyourstartup

📢Virtual Drug Discovery Startup Raises $35m to Revolutionize Medicine Relation Therapeutics Ltd, a virtual drug discovery company, has raised $35m in seed financing, bringing its total seed fundraise to $60m. The financing round was led by DCVC and co-led by NVIDIA's venture arm, with participation from existing and new investors. The funds will be used to accelerate the discovery of novel biology, targets, and medicines. Relation Therapeutics focuses on generative AI drug discovery. Their platform generates and analyzes human data to understand disease biology, discover novel targets, and develop medicines. Their current focus is on osteoporosis. #BioprocessUpdates #RelationTherapeutics #SeedFinancing #VirtualDrugDiscovery #DCVC #NVIDIAsVentureArm #Investors #Biology #Targets #Medicines #AI #DrugDiscovery #HumanData #DiseaseBiology #NovelTargets #Osteoporosis ▷ Read the full article here: 📎 https://lnkd.in/dAiFCPsk

🚀 Baltimore: A Hub of Innovation & Opportunity! 🌟 Exciting times ahead for the Greater Baltimore region as it solidifies its place as a powerhouse for entrepreneurship and investment! 💼✨ At the recent The Big Idea CONNECTpreneur Community event, five innovative companies showcased their groundbreaking ideas and are now raising capital to fuel their growth. Here’s a glimpse of what they’re bringing to the table: 1️⃣ Axcess Instruments - Revolutionizing Minimally Invasive Surgery with their 4K-enhanced AxcessPort™! 🏥 2️⃣ ChromaTan, Inc - Transforming biopharmaceutical production with column-free, single-use chromatography. 🧬 3️⃣ CraniUS - Innovating neurosurgical technology with NeuroPASS, delivering chronic medication directly to the brain! 🧠 4️⃣ 20/20 GeneSystems - Leading the way in cancer diagnostics and preventive medicine with advanced tools. 🎗️ 5️⃣ RoadDoc - Creating telemedicine platforms for mobile users, making healthcare accessible anytime, anywhere! 📱 Read more about these innovative companies in the full article! 📖🔗 https://lnkd.in/gf-Uz9rB #BaltimoreInnovation #CONNECTpreneur #Entrepreneurship #InvestmentOpportunities

Amber Therapeutics raises $100m - one of the largest series A's for a European Medtech 🇬🇧 💪 The UK-based medtech company has just closed their Series A financing round, raising $100 million (£80 million) from investors across the US and UK. This funding was led by New Enterprise Associates (NEA), and included F-Prime Capital, Lightstone Ventures, Intuitive Ventures, Oxford Science Enterprises, and 8VC. Amber is pioneering an adaptive #neuromodulation therapy, Amber-UI, to treat mixed urinary incontinence (MUI) - a condition affecting millions of women worldwide. Amber-UI is the first fully implantable therapy targeting the pudendal nerve, designed to address both urge and stress incontinence through a minimally invasive procedure. Aidan Crawley, CEO of Amber said: "Securing this significant financing round from such a blue-chip group of US and UK investors is a huge validation of our therapy value proposition and the quality of the team we have built". Amber-UI, powered by the Picostim System, offers a unique approach by dynamically adapting to physiological responses, aiming to restore normal bladder function. Early results from their initial study "Aura 2" look promising, showing safety and strong efficacy signals. #funding #neurotech